

PARTICIPANTS NEEDED!!



Rivastigmine in Parkinson's Disease

What is Rivastigmine?

An FDA-approved treatment of mild to moderate dementia associated with Parkinson's disease. This study will be using the patch form.

What is the purpose of the study?

To learn more about Rivastigmine's role in impacting cognition and gait/balance in those with Parkinson's disease.

Who are the eligible participants?

- You must have a diagnosis of Parkinson's disease.
- Able to walk independently or with an assisted device.
- Enrolled in our Database study, or willing to enroll prior to doing this study.
- Mild to moderate cognitive impairment, as determined by your health care provider.

What is expected of the participants?

- Complete a brief walking and balance test while wearing a device around your waist.
- Undergo a computerized cognitive assessment.
- Start an initial dose of rivastigmine after first study visit.
- Complete all 3 doses (increase in 4-week intervals), as tolerated.
- Return to complete the single follow up visit (same testing as initial) after 3 months.

How much time does it take to participate in the study?

This is a 3-month study with two total visits. The initial visit will take about an hour and a half. The follow up will be done after being on the medication for 3 months and will be the same amount of time.

Will I be compensated?

Yes, you will be given \$50 for completing the entire study.

**THIS STUDY IS
BEING
CONDUCTED AT:**

**UNIVERSITY OF
MARYLAND,
NEUROLOGY CLINIC**

BY: DR VON COELLN

CONTACT:

**UMB NEUROLOGY
RESEARCH
OFFICE**

**PHONE:
410-328-1883**

Coordinators:

Philip Heiser

Kimberly Bamarger

Veronica Fallon